Celon Pharma at the BIO International Convention 2019

The Company’s representatives will participate in the BIO International Convention 2019, an international convention which attracts over 16.000 biotechnology and pharmacy leaders each year. The conference allows for networking and collaboration in the field of drug development. Maciej Wieczorek, CEO of Celon Pharma S.A.: We can confirm the growing interest in our projects in theRead more »

FDA approved FGFR as new and validated molecular aim in cancer treatment

On 12 April 2019, the Food and Drug Administration (FDA) allowed the marketing of erdafitinib in urinary tract cancer treatment. This decision confirms the great potential of FGFR inhibitors in various solid cancers with FGFR aberrations and proves the recognition of this class medicines as new tools in advanced solid cancers treatment. Celon Pharma S.A.Read more »

#EPA2019 – presentation of the Company’s scientific and research projects as well as its generic portfolio during the most important event of European psychiatry

Celon Pharma S.A. representatives took part in the 27th European Congress of Psychiatry, EPA 2019, which was held from 6 to 9 April 2019 in Warsaw. Over 3,500 participants from all over the world took part in workshops, lectures and presentations devoted to the latest achievements in neuropsychiatry. The European Psychiatric Association is the biggestRead more »

Celon Pharma S.A. on #GPWInnovationDay 2019 on the way to a neuropsychiatric blockbuster

Representatives of the Company’s Management Board: Bogdan Manowski – Director for Business Development and dr Maciej Wieczorek – President of the Management Board, spoke at the GPW Innovation Day conference which is a meeting of investors with innovative companies including companies from biotechnology sector. During their presentation, the Management Board presented the current status ofRead more »

Celon Pharma increases the chances for a neuropsychiatric blockbuster and increases its export rates

Three active clinical programmes, including two regarding the most dynamic therapeutic area from the point of view of the next decade, which is neuropsychiatry, advanced pre-clinical development of drug candidates with innovative potential, continuation of construction of the largest Centre for Science and Research in Central and Eastern Europe together with a great financial resultRead more »

Celon Pharma on track to conquer the global antidepressant market worth between USD 2.5 and 4 billion.

International experts cooperating with the FDA have confirmed the efficacy and safety of eskatemine in treatment of unipolar, treatment-resistant depression, which might become the first cutting edge therapy for patients since the last innovation introduced 35 years ago. Celon Pharma develops this substance in two indications and is currently conducting phase II clinical trials. OnRead more »

Maciej Wieczorek on the strategies of developing innovative medicines at the 11th Multiciplinary conference on pharmaeutical science “Science for the Industry, Industry for science”

On 16 November this year,  President of the Management Board of Celon Pharma S.A. will give a lecture discussing the discovery and implementation of innovations in the pharmaceutical sector on the example of drug candidates developed under Celon Pharma’s clinical programmes. He will also participate in an expert debate entitled: “Business for science”. We encourageRead more »